SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCSeptember 23, 2026

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Zidesamtinib produced an objective response in 94% of the 94 efficacy-evaluable patients in the ROS1 TKI-naive cohort of ARROS-1, a result presented in a Presidential Symposium session at the 2026 World Conference on Lung Cancer in Seoul. Median follow-up was 15.2 months at a data cut-off of 16 April 2026, and median progression-free survival had not been reached. GSK states that the result will support a supplemental New Drug Application to the US Food and Drug Administration this year to extend the drug's indication into first-line use.
Share
Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

In brief

  • Zidesamtinib produced an objective response in 94% of the 94 efficacy-evaluable patients in the ROS1 tyrosine kinase inhibitor (TKI)-naive cohort of ARROS-1 (88/94; 95% CI 87 to 98), with a complete response in 15% (14/94).
  • Patients were naive to a ROS1 TKI but not untreated: up to one prior line of chemotherapy and/or immunotherapy was permitted, and 27% had received prior chemotherapy.
  • Responses were durable, with 94% of patients continuing to respond at nine months and 86% at 12 months, and median progression-free survival had not been reached.
  • All ten patients with measurable brain metastases at baseline responded (95% CI 69 to 100), seven of them completely, and no central nervous system progression was seen in patients who had no brain metastases at baseline.
  • Zidesamtinib is not approved anywhere as a first-line treatment. GSK states that these data will support a supplemental New Drug Application to the US Food and Drug Administration this year.

Study at a glance

  • Source trial: ARROS-1 (NCT05118789), a global single-arm first-in-human phase I/II trial, described by GSK as registrational; data cut-off 16 April 2026
  • Agent: Zidesamtinib 100 mg once daily, sold as Jideytro
  • Cohort: The phase II cohort naive to ROS1 TKI therapy, with up to one prior line of chemotherapy and/or immunotherapy permitted; 532 patients have received the drug across all lines and 183 as their first TKI
  • Efficacy-evaluable population (n=94): Patients with measurable disease by blinded independent central review who started treatment by 15 June 2025, giving at least nine months of follow-up for duration of response; 27% had prior chemotherapy and 17% had baseline central nervous system metastases
  • Endpoint reported: Objective response rate 94% (88/94; 95% CI 87 to 98) and complete response rate 15% (14/94)
  • Durability: 94% of patients continuing to respond at nine months and 86% at 12 months; 90% progression-free at 12 months; median progression-free survival and median duration of response not reached
  • Intracranial results: All ten patients with measurable brain metastases at baseline responded (95% CI 69 to 100), seven with complete clearance; 78% maintained an intracranial response at 12 months; no central nervous system progression in patients without baseline brain metastases
  • Safety: Treatment-related adverse events gave dose reductions in 11% of patients and discontinuation in 1%; most events were low grade
  • Not reported: Rates for individual adverse events, grade 3 or higher toxicity rates, and overall survival

A 94% response rate among 94 evaluable patients, 15% of them complete

The 94 patients are the efficacy-evaluable population rather than the whole cohort. They had measurable disease by blinded independent central review and had started zidesamtinib by 15 June 2025, a cut-off chosen so that every one of them had at least nine months of follow-up available for duration of response.

Eighty-eight of the 94 responded and 14 had no measurable disease left, giving a 95% confidence interval of 87% to 98% around the response rate. GSK does not state who assessed response.

Responses held in 86% of patients at 12 months, with median progression-free survival not reached

Median follow-up was 15.2 months, with individual patients followed for between 1.1 and 30.5 months, at a data cut-off of 16 April 2026. Durability was reported at landmarks rather than as medians: 94% of patients were continuing to respond at nine months, 86% at 12 months, and 90% were progression-free at 12 months.

Neither median progression-free survival nor median duration of response had a value at this analysis, which on a trial whose longest-followed patient has reached 30.5 months is a statement about how few events have accrued.

All ten patients with measurable brain metastases responded, seven with complete clearance

Seventeen per cent of the evaluable population had central nervous system metastases at baseline, and ten of them had intracranial disease large enough to measure. Every one of the ten responded, with a confidence interval running from 69% to 100%, and in seven the detectable brain tumour cleared entirely. At 12 months, 78% of patients maintained an intracranial response.

GSK also reports no central nervous system progression events among patients who entered the trial without brain metastases. That is the stronger of the two intracranial claims, because it rests on that whole group rather than on ten patients, although no follow-up time is given for it.

Dose reductions in 11% of patients and discontinuation in 1%

The treatment-related events GSK reports in at least 15% of patients were peripheral oedema, weight increase, raised blood creatine phosphokinase, altered taste and raised aspartate aminotransferase. Most events were low grade.

One per cent of patients stopped for a treatment-related event. ROS1-positive disease accounts for roughly 2% of non-small cell lung cancers, an estimated 50,000 new diagnoses worldwide each year.

“Patients with ROS1-positive NSCLC may receive treatment for many years while continuing to work, care for their families and live their daily lives. They need treatments that provide lasting control of their disease, including in the brain, while limiting side effects and treatment disruption. The durable responses and low rates of treatment discontinuation observed in ARROS-1 represent encouraging progress toward addressing these long-term treatment needs.”Alexander Drilon, MD, ARROS-1 primary investigator and Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center states that Drilon has financial interests related to Nuvalent, Inc.

The drug is approved only after a prior TKI, and ARROS-1 carries no comparator arm

The US Food and Drug Administration approved zidesamtinib in July 2026 for patients with ROS1-positive NSCLC previously treated with a TKI, and the drug is not approved anywhere in the world as a first-line therapy.

ARROS-1 is single-arm, so the 94% figure has no randomised comparison behind it. Patients had received no previous ROS1 TKI, although 27% had prior chemotherapy and 17% of those had prior immunotherapy as well, so this is a population whose targeted treatment starts with the drug rather than a treatment-naive one.

Sources

  1. GSK. GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first-line ROS1-positive non-small cell lung cancer (2026-09-13). gsk.com

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard